The main purpose of conducting this study was to identify the patients’ expectations and level of treatment satisfaction, as well as the clinical management of patients with moderate/severe allergic rhinoconjunctivitis treated with GRAZAX®.
The study design used to explore the phenomena was a non-interventional, observational, multi-center, open-label study. It was involving a total of 131 adult patients aged 18–66 years with a confirmed diagnosis of grass-allergy and initiated treatment with GRAZAX®.
56.6% of patients stated that their symptoms were much less/less intense, 86% needed less symptomatic medication for control of their symptoms, and 74.4% manifested to have improved as regards their allergic disease since treatment was initiated as compared with previous grass pollen season. The patient satisfaction was measured by using a VAS between 0 and 100 comprising five different items: effectiveness, tolerability, cost, convenience, and overall satisfaction.
Through the findings of this study, the researchers concluded that improved communication leads to increased patient knowledge, greater patient compliance, and increased patient satisfaction.
Reference: https://clinicalmolecularallergy.biomedcentral.com/articles/10.1186/s12948-016-0057-9
